Rxo (RXO) Payables (2021 - 2026)

Rxo (RXO) has reported Payables for 6 consecutive years, with $713.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Payables rose 54.66% year-over-year to $713.0 million; the trailing twelve-month figure through Jun 2026 stood at $713.0 million (up 54.66% YoY), and the FY2025 full-year result was $539.0 million, down 5.11% from the prior year.
• Payables climbed to $713.0 million in Q2 2026 per RXO's latest filing, from $584.0 million in the prior quarter.
• Across five years, Payables topped out at $713.0 million in Q2 2026 and bottomed at $372.0 million in Q1 2024.
• Historically, Payables has averaged $500.5 million across 5 years, with a median of $497.0 million in 2023.
• The sharpest annual moves came in 2024 and 2026: Payables declined 25.0% in 2024, then soared 54.66% in 2026.
• Over 5 years, Payables stood at $501.0 million in 2022, then declined by 17.37% to $414.0 million in 2023, then soared by 37.2% to $568.0 million in 2024, then decreased by 5.11% to $539.0 million in 2025, then surged by 32.28% to $713.0 million in 2026.
• According to Business Quant data, Payables over the past three periods registered $713.0 million, $584.0 million, and $539.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.